Novel theranostic nanoagent based on CuMo2S3-PEG-Gd for MRI-guided photothermal/photodynamic/chemodynamic therapy

Cancer is a severe disease, which have troubled human being for a long time. The development of nanotechnology has provided a new way for cancer treatment. It is a promising strategy to integrate imaging and therapeutic functions into one single nanoplatform to achieve efficient combination of diagnosis and treatment. Herein, we exploited novel CuMo2S3-PEG-Gd nanocomposites (NCs) for magnetic resonance imaging (MRI), guiding the photothermal therapy (PTT)/photodynamic therapy (PDT)/chemodynamic therapy (CDT). The experimental results showed that CuMo2S3-PEG-Gd NCs have a high photothermal conversion efficiency (40.6%), excellent biocompatibility and good biosecurity. The CuMo2S3-PEG-Gd NCs exhibited a clear MRI performance for tumor due to connecting Gd, which can guide in vivo therapy to improve the therapeutic effect. Moreover, both in vitro and in vivo therapeutic results of CuMo2S3-PEG-Gd NCs exhibited that the PTT/PDT/CDT achieved a remarkably synergistic effect, which could efficiently inhibit the tumor growth. Thus, CuMo2S3-PEG-Gd NCs, which integrated imaging with multiple therapies, have a good potential as theranostic agent for tumor.

Automated summary

The novel CuMo2S3-PEG-Gd nanocomposites have shown promising results in cancer treatment, with high photothermal conversion efficiency, excellent biocompatibility, and good biosecurity. They also demonstrate clear MRI performance for tumor guidance and a remarkable synergistic effect in both in vitro and in vivo PTT/PDT/CDT, efficiently inhibiting tumor growth. Overall, CuMo2S3-PEG-Gd nanocomposites have great potential as theranostic agents for tumors.